Navigation Links
Metabolix Announces Promotion of Johan van Walsem to Chief Operating Officer

CAMBRIDGE, Mass., July 17, 2013 /PRNewswire/ -- Metabolix, Inc. (NASDAQ: MBLX), an innovation-driven bioscience company delivering sustainable solutions to the plastics, chemicals and energy industries, announced today that Johan van Walsem has been promoted to the position of Chief Operating Officer (COO), effective Monday, July 22. In this newly created role, Mr. van Walsem will be responsible for the management of the Company's biopolymers, biobased chemicals and crops businesses, as well as the key functional areas that enable these businesses to perform. He will continue to report to Metabolix President and Chief Executive Officer, Richard P. Eno.

(Logo: ) 

"We are excited to appoint Johan to the position of COO of Metabolix, where he has taken on increasing levels of responsibility throughout his tenure," said Mr. Eno. "He has led critical functions across each of our three business platforms: biopolymers, biobased chemicals and crops, and as a result, will be able to very effectively integrate our functional expertise for maximum commercial impact.

"During the past 16 months, we have redefined our biopolymer commercial strategy around high-value markets, set up global supply chains for biopolymers, built the initial customer base and advanced our manufacturing technology to lower overall costs," Mr. Eno said. "We also have continued to achieve technical milestones in our biobased chemicals platform and have the potential to create a highly differentiated chemicals business. The creation of the chief operating officer role allows for clear focus on the execution of these businesses. I look forward to working together with Johan to drive further growth in the coming years."

Mr. van Walsem most recently served as the Company's Vice President of Manufacturing and Product Development. He has more than 20 years of experience in the processing industry, with more than 15 years' experience leading development and manufacturing efforts for large-scale, fermentation-based processes. He also has been integral in the development of the manufacturing process for the Company's Mirel biopolymer products. He received a Master's degree in Chemical Engineering from the University of Pretoria in 1986 and an M.B.A. from the University of South Africa in 1995.

About Metabolix
Metabolix, Inc. is an advanced biomaterials company that is well positioned to address growing market demand for sustainable solutions in the plastics, chemicals and energy industries. The Company is developing and commercializing a family of high-performance biopolymers targeted to the markets for film and bag applications, performance additives and functional biodegradation. Metabolix's biobased chemicals platform is focused on high-value segments and applications using its novel "FAST" recovery process. The Company also is developing a platform for co-producing plastics, chemicals and energy from crops. Metabolix has established an industry-leading intellectual property portfolio that, together with its knowledge of advanced industrial practice, provides a foundation for industry collaborations.

For more information, please visit

Safe Harbor for Forward-Looking Statements

This press release contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements in this release do not constitute guarantees of future performance. Investors are cautioned that statements in this press release which are not strictly historical statements, including, without limitation, statements regarding expectations for the Company's growth, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including the risks and uncertainties detailed in Metabolix's filings with the Securities and Exchange Commission. Metabolix assumes no obligation to update any forward-looking information contained in this press release or with respect to the announcements described herein.


SOURCE Metabolix, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Metabolix Executives to Present at Leading Industry Conferences
2. Revolutionary Science Announces the Expansion of the Saniclave Product Line
3. BioSpecifics Technologies Corp. Announces Partnership between Auxilium and Swedish Orphan Biovitrum AB for XIAPEX in Eurasia and Africa
4. Alkemists Labs Announces the Expansion of Its New R&D Division
5. Nanounity Announces New Characterization Tools for the 2013 Microscopy & Microanalysis Annual Meeting in Indianapolis, August 4-8
6. InstantGMP Announces Addition of Cost and Pricing Model to Electronic Batch Records in Their Manufacturing Execution System
7. Saint Lukes Neuroscience Institute Announces 2013 Symposium
8. Elsevier Announces 2013 Library Connect Charleston Conference Award
9. Elsevier Announces 2012 Journal Impact Factor Highlights
10. Cancer Advances Announces Allowance of a New Patent to Its Suite of Gastrin Inhibitor Products
11. Generex Announces Particulars of Conference Call with Members of the Antigen Express Scientific Advisory Board
Post Your Comments:
(Date:11/26/2015)... , England , November 26, 2015 /PRNewswire/ ... Medical, an innovative medical device company specializing in imaging technologies, ... from the European Commission as part of the Horizon 2020 ... company to carry out a large-scale clinical trial in breast ...      (Logo: , --> ...
(Date:11/25/2015)... , Nov. 25, 2015  PharmAthene, Inc. (NYSE ... has adopted a stockholder rights plan (Rights Plan) in ... operating loss carryforwards (NOLs) under Section 382 of the ... --> PharmAthene,s use of its NOLs could ... change" as defined in Section 382 of the Code. ...
(Date:11/25/2015)... -- Studies reveal the differences in species ... the way for more effective treatment for one of the ... --> --> Gum disease ... cats, yet relatively little was understood about the bacteria associated ... conducted by researchers from the WALTHAM Centre for Pet Nutrition ...
(Date:11/25/2015)... DIEGO , Nov. 25, 2015  Neurocrine Biosciences, ... Kevin Gorman , President and CEO of Neurocrine Biosciences, ... Healthcare Conference in New York . ... to visit the website approximately 5 minutes prior to ... A replay of the presentation will be available on ...
Breaking Biology Technology:
(Date:11/18/2015)... , November 18, 2015 ... has published a new market report titled  Gesture Recognition ... and Forecast, 2015 - 2021. According to the report, the global ... and is anticipated to reach US$29.1 bn by 2021, ... North America dominated the ...
(Date:11/16/2015)... Nov 16, 2015  Synaptics Inc. (NASDAQ: ... solutions, today announced expansion of its TDDI product ... touch controller and display driver integration (TDDI) solutions ... These new TDDI products add to the previously-announced ... TD4302 (WQHD resolution), and TD4322 (FHD resolution) solutions. ...
(Date:11/10/2015)... LONDON , Nov. 10, 2015 /PRNewswire/ ... segmented on the basis of product, type, ... segments included in this report are consumables, ... this report are safety biomarkers, efficacy biomarkers, ... in this report are diagnostics development, drug ...
Breaking Biology News(10 mins):